AR093479A1 - Polipeptidos para el transporte de barrera hematoencefalica - Google Patents

Polipeptidos para el transporte de barrera hematoencefalica

Info

Publication number
AR093479A1
AR093479A1 ARP130104184A ARP130104184A AR093479A1 AR 093479 A1 AR093479 A1 AR 093479A1 AR P130104184 A ARP130104184 A AR P130104184A AR P130104184 A ARP130104184 A AR P130104184A AR 093479 A1 AR093479 A1 AR 093479A1
Authority
AR
Argentina
Prior art keywords
polypeptide
amino acids
length
less
bbb
Prior art date
Application number
ARP130104184A
Other languages
English (en)
Inventor
Borros Gomez Salvador
Xavier Rivero Monso Francesc
Cascante Cirera Anna
Original Assignee
Sagetis Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sagetis Biotech Sl filed Critical Sagetis Biotech Sl
Publication of AR093479A1 publication Critical patent/AR093479A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica que comprende el polipéptido o conjugado enseñado para el tratamiento de una enfermedad neurológica, tumor cerebral, metástasis cerebral, esquizofrenia, epilepsia, etc. Reivindicación 1: Un polipéptido para cruzar la barrera hematoencefálica (BBB, por sus siglas en inglés), donde el polipéptido es: (a) un polipéptido regulón con menos de 59 aminoácidos de longitud, que comprende 7 o más aminoácidos consecutivos de la SEC ID Nº 2; y comprende K48 y R49 (numerados respecto de la SEC ID Nº 1); (b) un polipéptido de RAP con menos de 100 aminoácidos de longitud, que comprende al menos 20 aminoácidos consecutivos de la SEC ID Nº 4; (c) un polipéptido flexible con menos de 100 aminoácidos de longitud, que comprende un bucle flexible y donde el polipéptido comprende la siguiente secuencia: X¹X²EX³X⁴X⁵X⁶RGKRX⁷X⁸X⁹KDEX¹⁰X¹¹ o bien: RGKRX⁷X⁸X⁹KDE donde X¹ = A, F, S o T; X² = G, K, R o S; X³ = S o T; X⁴ = N o S; X⁵ = A, I o T; X⁶ = I, T o V; X⁷ = D, E o G; X⁸ = S, T o Y; X⁹ = F, T o Y; X¹⁰ = G o N; X¹¹ = K o R; o (d) un polipéptido rígido con menos de 100 aminoácidos de longitud, que comprende una hélice a y comprende la siguiente secuencia consenso: (K/R)A(A/E/Q)KA(A/E/Q)A(K/R), en forma opcional GD(A/E)ₐ(K/R)A(A/E/Q)KA(A/E/Q)A(K/R)AXᵇGY donde, de preferencia, a está comprendido entre 1 y 10, y b está comprendido entre 1 y 25. Reivindicación 6: Un conjugado para el transporte de un agente a través de la barrera hematoencefálica (BBB), que comprende: (a) un péptido de acuerdo con una cualquiera de las reivindicaciones anteriores, y (b) un agente, donde el conjugado es capaz de cruzar la BBB.
ARP130104184A 2012-11-14 2013-11-14 Polipeptidos para el transporte de barrera hematoencefalica AR093479A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1220474.9A GB201220474D0 (en) 2012-11-14 2012-11-14 Polypeptides

Publications (1)

Publication Number Publication Date
AR093479A1 true AR093479A1 (es) 2015-06-10

Family

ID=47470579

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104184A AR093479A1 (es) 2012-11-14 2013-11-14 Polipeptidos para el transporte de barrera hematoencefalica

Country Status (14)

Country Link
US (1) US20150376237A1 (es)
EP (1) EP2919798A1 (es)
JP (1) JP2016539076A (es)
KR (1) KR20150100655A (es)
CN (1) CN104968359A (es)
AR (1) AR093479A1 (es)
AU (1) AU2013346420A1 (es)
CA (1) CA2890704A1 (es)
GB (1) GB201220474D0 (es)
HK (1) HK1213789A1 (es)
MX (1) MX2015005948A (es)
RU (1) RU2015122666A (es)
TW (1) TW201427994A (es)
WO (1) WO2014076655A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006272405B2 (en) 2005-07-15 2013-02-07 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
CA2881602A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
SG11201609911YA (en) * 2014-05-28 2016-12-29 Nono Inc Chloride salt of tat-nr2b9c
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
ES2882255T3 (es) 2015-07-01 2021-12-01 California Inst Of Techn Sistemas de administración basados en polímeros de ácido múcico catiónicos
WO2017205302A1 (en) 2016-05-23 2017-11-30 California Institute Of Technology Regulate gut microbiota to treat neurodegenerative disorders
US10702589B2 (en) 2016-10-04 2020-07-07 Ann And Robert H. Lurie Children's Hospital Of Chicago Compositions and methods of treating neurological disorder and stress-induced conditions
CA3097521C (en) 2017-05-15 2023-10-17 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
CN109422801B (zh) * 2017-08-31 2022-07-08 复旦大学 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途
US20190381188A1 (en) * 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
KR102320650B1 (ko) * 2019-10-16 2021-11-04 주식회사 시선테라퓨틱스 혈뇌장벽 투과능을 가지는 펩티드 핵산 복합체 및 이를 포함하는 조성물
JP2023506703A (ja) 2019-12-04 2023-02-20 ダンタリ インコーポレイテッド 治療用ナノ粒子を合成するための方法及び組成物
CA3176495A1 (en) * 2020-04-27 2021-11-04 Aruna Bio, Inc. Binding agents and uses thereof for central nervous system delivery
WO2023128122A1 (ko) * 2021-12-29 2023-07-06 주식회사 펩스젠 혈액뇌장벽 투과능을 가지는 펩타이드 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
ATE230389T1 (de) * 1995-10-25 2003-01-15 Senju Pharma Co Angiogenese inhibitoren
JP3996659B2 (ja) * 1995-10-25 2007-10-24 千寿製薬株式会社 血管新生抑制剤
EP0928786B1 (en) * 1995-10-25 2003-01-02 Senju Pharmaceutical Co., Ltd. Angiogenesis inhibitor
US7361821B2 (en) * 2002-09-20 2008-04-22 Intel Corporation Controlled alignment of nanobarcodes encoding specific information for scanning probe microscopy (SPM) reading
WO2008036682A2 (en) * 2006-09-18 2008-03-27 Raptor Pharmaceutical Inc. Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates
CA2681522A1 (en) * 2007-03-21 2008-09-25 Raptor Pharmaceutical Inc. Cyclic receptor-associated protein (rap) peptides
WO2009075836A2 (en) * 2007-12-10 2009-06-18 The Brigham And Women's Hospital, Inc. Rap variants for drug delivery
WO2010088729A1 (en) * 2009-02-04 2010-08-12 University Of Tasmania Through The Menzies Research Institute Compositions and uses therefor
WO2011119608A1 (en) * 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
EP2706989A1 (en) * 2011-05-09 2014-03-19 Instituto Químico De Sarrià Polymeric nanoparticles for drug delivery

Also Published As

Publication number Publication date
US20150376237A1 (en) 2015-12-31
CN104968359A (zh) 2015-10-07
GB201220474D0 (en) 2012-12-26
HK1213789A1 (zh) 2016-07-15
CA2890704A1 (en) 2014-05-22
MX2015005948A (es) 2015-12-01
AU2013346420A1 (en) 2015-05-28
EP2919798A1 (en) 2015-09-23
JP2016539076A (ja) 2016-12-15
WO2014076655A1 (en) 2014-05-22
TW201427994A (zh) 2014-07-16
KR20150100655A (ko) 2015-09-02
RU2015122666A (ru) 2017-01-10

Similar Documents

Publication Publication Date Title
AR093479A1 (es) Polipeptidos para el transporte de barrera hematoencefalica
BR112013026032A2 (pt) composições nutricionais incluindo ácidos graxos de cadeia ramificada para cicatrização de ferida
MX2020001337A (es) Formulaciones que comprenden un acido nucleico en una alta concentracion.
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
Alsultan et al. Fetal hemoglobin in sickle cell anemia: Saudi patients from the Southwestern province have similar HBB haplotypes but higher HbF levels than African Americans
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
HRP20171931T1 (hr) Farmaceutska formulacija koja obuhvaća biofarmaceutski lijek
BR112014007069A2 (pt) proteínas de fusão para o tratamento de distúrbios metabólicos
WO2012149365A3 (en) Antibodies selective for pathological tau dimers and oligomers and their uses in treatment, diagnosis, monitoring of tauopathies
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
CL2012001186A1 (es) Peptido fosforilado o sal farmaceuticamente aceptable del mismo que activa la guanilato ciclasa c en el sistema gastrointestinal superior; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno gastrointestinal.
PE20180128A1 (es) Compuestos antisenescentes y usos de los mismos
NZ608502A (en) Polypeptides that bind to human complement component c5
RU2017125931A (ru) Фармацевтическая композиция, содержащая плазминоген, и ее применение
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
AR068020A1 (es) Terapia combinada para el cancer de pancreas usando un peptido antigenico y un agente quimioterapeutico
BR112015000183A2 (pt) proteínas de superfície específicas de variante (vsp) de protozoário como carreadores para entrega de fármaco oral
RU2017114673A (ru) Слитый белок, наночастица, состоящая из множества мономеров указанного слитого белка, и их применение
BR112015013708A2 (pt) polipeptídeo compreendendo uma proteína igf-1 humana, polinucleotídeo, composição farmacêutica e uso
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
JP2015514115A5 (es)
JP2012102105A5 (es)
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.

Legal Events

Date Code Title Description
FB Suspension of granting procedure